# VectorY raises €74.5 million to advance ALS therapy trial

_Published Friday, November 13, 2026 at 1:06 PM EST · Capital · Latest · Tier 2 — Notable_

![VectorY raises €74.5 million to advance ALS therapy trial — EU-Startups](https://www.eu-startups.com/wp-content/uploads/2026/11/Untitled-Design-2026-11-13T123237.895.jpg)

VectorY Therapeutics has raised €74.5 million ($83.5 million) to advance its experimental therapies for neurodegenerative diseases. New investors include Angelini Ventures, Invest-NL and the European Investment Bank, alongside returning backers.

The financing will mainly support VTx-002 in its ongoing PIONEER-ALS Phase 1/2 trial in adults with ALS across the US, Europe and the UK. VectorY combines therapeutic antibodies with one-time viral delivery directly to the central nervous system. The money will also support its Huntington's disease programme and other preclinical work; the ALS treatment remains investigational.

## Sources

- [EU-Startups](https://www.eu-startups.com/2026/11/amsterdams-vectory-therapeutics-raises-e74-5-million-to-tackle-als-and-other-neurodegenerative-diseases/)

---
Canonical: https://techandbusiness.org/newswire/bkn-q9paaIUpYclIuXElMO
Published: 2026-11-13T18:06:20.647Z
Story chronology: 2026-11-13T07:11:42.000Z
Retrieved: 2026-11-13T19:56:36.094Z
Publisher: Tech & Business (techandbusiness.org)